Abstract
Several technologies are now available to treat whole fresh-frozen plasma (FFP) to inactivate transfusion-transmitted viruses, including pasteurisation, solvent/detergent and methylene blue/light. The first two involve creating large plasma pools prior to inactivation, while only pasteurisation clearly destroys both enveloped and non-enveloped viruses. Some of the issues surrounding the use of these products include demonstration of both clinical efficacy and improved viral safety, and the need for product licencing. Potential benefits must be balanced against the risks of plasma pooling, while the increased costs will require comparison with other strategies such as quarantining of plasma. It is also recognised that reducing inappropriate FFP usage will play a role in improved patient safety.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
